Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation

Donghong Zhang, Jinli Lou, Xu Zhang, Lin Zhang, Fei Wang, Danfei Xu, Na Niu, Yidong Wang, Yue Wu, Wei Cui

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hyperhomocysteinemia (HHcy) can result from liver disease or dysfunction and further alters intracellular lipid metabolism. Cytochrome P450 (CYP) arachidonic acid epoxygenases are expressed in human cancers and promote cancer metastasis. This study explored the interaction of Hcy and CYP450 metabolism in hepatocellular carcinoma (HCC). The levels of 4-epoxyeicosatrienoic acid (EET) isomers and their generative enzyme CYP2J2 level as well as intracellular Hcy level were higher in 42 cases of HCC than in paired non-tumor tissue. Elevated Hcy-decreased DNA methylation on SP1/AP1 binding motifs and enhancement on the CYP2J2 promoter via ERK1/2 signaling was essential for CYP2J2 upregulation and EET metabolism. Increased Hcy level enhanced the neoplastic cellular phenotype, which was reversed by CYP2J2 knockdown in vitro. Furthermore, tumor growth and size as well as patterns of CYP2J2 expression and DNA demethylation were increased with HHcy in mice induced orthotopically by 2% (wt/wt) L-methionine with or without folate deficiency. Moreover, the effect was attenuated by shRNA knockdown of CYP2J2. Thus, HHcy results from but can also promote hepatocarcingenesis via CYP450-EET metabolism by crosstalk of DNA demethylation of CYP2J2 and ERK1/2 signaling.

Original languageEnglish (US)
Pages (from-to)15377-15392
Number of pages16
JournalOncotarget
Volume8
Issue number9
DOIs
StatePublished - 2017

Fingerprint

Hyperhomocysteinemia
DNA Methylation
Hepatocellular Carcinoma
Acids
Liver Diseases
Neoplasms
DNA
arachidonate epoxygenase
Lipid Metabolism
Folic Acid
Arachidonic Acid
Methionine
Cytochrome P-450 Enzyme System
Small Interfering RNA
Up-Regulation
Neoplasm Metastasis
Phenotype
Enzymes
Growth

Keywords

  • CYP2J2
  • CYP450
  • DNA methylation
  • Hepatocellular carcinoma
  • Homocysteine

ASJC Scopus subject areas

  • Oncology

Cite this

Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation. / Zhang, Donghong; Lou, Jinli; Zhang, Xu; Zhang, Lin; Wang, Fei; Xu, Danfei; Niu, Na; Wang, Yidong; Wu, Yue; Cui, Wei.

In: Oncotarget, Vol. 8, No. 9, 2017, p. 15377-15392.

Research output: Contribution to journalArticle

Zhang, D, Lou, J, Zhang, X, Zhang, L, Wang, F, Xu, D, Niu, N, Wang, Y, Wu, Y & Cui, W 2017, 'Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation', Oncotarget, vol. 8, no. 9, pp. 15377-15392. https://doi.org/10.18632/oncotarget.14165
Zhang, Donghong ; Lou, Jinli ; Zhang, Xu ; Zhang, Lin ; Wang, Fei ; Xu, Danfei ; Niu, Na ; Wang, Yidong ; Wu, Yue ; Cui, Wei. / Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation. In: Oncotarget. 2017 ; Vol. 8, No. 9. pp. 15377-15392.
@article{7739210ca2cf4f0889893073123c8510,
title = "Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation",
abstract = "Hyperhomocysteinemia (HHcy) can result from liver disease or dysfunction and further alters intracellular lipid metabolism. Cytochrome P450 (CYP) arachidonic acid epoxygenases are expressed in human cancers and promote cancer metastasis. This study explored the interaction of Hcy and CYP450 metabolism in hepatocellular carcinoma (HCC). The levels of 4-epoxyeicosatrienoic acid (EET) isomers and their generative enzyme CYP2J2 level as well as intracellular Hcy level were higher in 42 cases of HCC than in paired non-tumor tissue. Elevated Hcy-decreased DNA methylation on SP1/AP1 binding motifs and enhancement on the CYP2J2 promoter via ERK1/2 signaling was essential for CYP2J2 upregulation and EET metabolism. Increased Hcy level enhanced the neoplastic cellular phenotype, which was reversed by CYP2J2 knockdown in vitro. Furthermore, tumor growth and size as well as patterns of CYP2J2 expression and DNA demethylation were increased with HHcy in mice induced orthotopically by 2{\%} (wt/wt) L-methionine with or without folate deficiency. Moreover, the effect was attenuated by shRNA knockdown of CYP2J2. Thus, HHcy results from but can also promote hepatocarcingenesis via CYP450-EET metabolism by crosstalk of DNA demethylation of CYP2J2 and ERK1/2 signaling.",
keywords = "CYP2J2, CYP450, DNA methylation, Hepatocellular carcinoma, Homocysteine",
author = "Donghong Zhang and Jinli Lou and Xu Zhang and Lin Zhang and Fei Wang and Danfei Xu and Na Niu and Yidong Wang and Yue Wu and Wei Cui",
year = "2017",
doi = "10.18632/oncotarget.14165",
language = "English (US)",
volume = "8",
pages = "15377--15392",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "9",

}

TY - JOUR

T1 - Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation

AU - Zhang, Donghong

AU - Lou, Jinli

AU - Zhang, Xu

AU - Zhang, Lin

AU - Wang, Fei

AU - Xu, Danfei

AU - Niu, Na

AU - Wang, Yidong

AU - Wu, Yue

AU - Cui, Wei

PY - 2017

Y1 - 2017

N2 - Hyperhomocysteinemia (HHcy) can result from liver disease or dysfunction and further alters intracellular lipid metabolism. Cytochrome P450 (CYP) arachidonic acid epoxygenases are expressed in human cancers and promote cancer metastasis. This study explored the interaction of Hcy and CYP450 metabolism in hepatocellular carcinoma (HCC). The levels of 4-epoxyeicosatrienoic acid (EET) isomers and their generative enzyme CYP2J2 level as well as intracellular Hcy level were higher in 42 cases of HCC than in paired non-tumor tissue. Elevated Hcy-decreased DNA methylation on SP1/AP1 binding motifs and enhancement on the CYP2J2 promoter via ERK1/2 signaling was essential for CYP2J2 upregulation and EET metabolism. Increased Hcy level enhanced the neoplastic cellular phenotype, which was reversed by CYP2J2 knockdown in vitro. Furthermore, tumor growth and size as well as patterns of CYP2J2 expression and DNA demethylation were increased with HHcy in mice induced orthotopically by 2% (wt/wt) L-methionine with or without folate deficiency. Moreover, the effect was attenuated by shRNA knockdown of CYP2J2. Thus, HHcy results from but can also promote hepatocarcingenesis via CYP450-EET metabolism by crosstalk of DNA demethylation of CYP2J2 and ERK1/2 signaling.

AB - Hyperhomocysteinemia (HHcy) can result from liver disease or dysfunction and further alters intracellular lipid metabolism. Cytochrome P450 (CYP) arachidonic acid epoxygenases are expressed in human cancers and promote cancer metastasis. This study explored the interaction of Hcy and CYP450 metabolism in hepatocellular carcinoma (HCC). The levels of 4-epoxyeicosatrienoic acid (EET) isomers and their generative enzyme CYP2J2 level as well as intracellular Hcy level were higher in 42 cases of HCC than in paired non-tumor tissue. Elevated Hcy-decreased DNA methylation on SP1/AP1 binding motifs and enhancement on the CYP2J2 promoter via ERK1/2 signaling was essential for CYP2J2 upregulation and EET metabolism. Increased Hcy level enhanced the neoplastic cellular phenotype, which was reversed by CYP2J2 knockdown in vitro. Furthermore, tumor growth and size as well as patterns of CYP2J2 expression and DNA demethylation were increased with HHcy in mice induced orthotopically by 2% (wt/wt) L-methionine with or without folate deficiency. Moreover, the effect was attenuated by shRNA knockdown of CYP2J2. Thus, HHcy results from but can also promote hepatocarcingenesis via CYP450-EET metabolism by crosstalk of DNA demethylation of CYP2J2 and ERK1/2 signaling.

KW - CYP2J2

KW - CYP450

KW - DNA methylation

KW - Hepatocellular carcinoma

KW - Homocysteine

UR - http://www.scopus.com/inward/record.url?scp=85014127223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014127223&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14165

DO - 10.18632/oncotarget.14165

M3 - Article

VL - 8

SP - 15377

EP - 15392

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 9

ER -